Open AccessScreening studies of antimicrobial activity of pyrimidine derivative
Author(s) -
А. А. Цибизова,
A. L. Yasenyavskaya,
А. А. Озеров,
I. N. Tyurenkov,
Olga Bashkina,
М. А. Самотруева
Publication year - 2021
Publication title -
sibirskij naučnyj medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2410-2520
pISSN - 2410-2512
DOI - 10.18699/ssmj20210606
Subject(s) - staphylococcus aureus , klebsiella pneumonia , antimicrobial , microbiology and biotechnology , norfloxacin , serial dilution , antibacterial activity , chemistry , streptococcus pyogenes , biology , antibiotics , medicine , bacteria , ciprofloxacin , genetics , alternative medicine , pathology
Aim of the study was to screen the antimicrobial activity of pyrimidine derivative 3-[2-(1-naphthyl)-2-oxoethyl]-6-bromoquinazoline-4(3H)-oh with laboratory cipher VMA–13–06 in relation to pathogenic and opportunistic flora. Material and methods. Antimicrobial activity of VMA–13–06 was established in vitro against strains of Staphylococcus aureus, Klebsiella pneumonia, Streptococcus pyogenes, Escherichia coli, Acinetobacter baumannii and Citrobacter freundii by the method of serial dilutions, by forming rows with different concentrations of the compound under study. Results. VMA–13–06 was found to exhibit high antibacterial activity against S. aureus, S. pyogenes, E. coli and K. pneumonia at concentrations of 128 and 64 μg/ml comparable to the activity of the comparison drug norfloxacin. At a concentration of 32 μg/ml, the studied derivative is highly active against S. aureus and S. pyogenes and shows average activity against E. coli and K. pneumonia. The compound VMA–13–06 in dilution from 16 to 4 μg/ml is moderately active against the above-mentioned microorganisms. At concentrations from 2 to 0.25 μg/ml, the pyrimidine derivative is inactive against S. aureus, S. pyogenes, E. coli and K. pneumonia, in all dilutions – against C. freundii and A. baumannii. Conclusions. The results of a screening study indicate a pronounced bactericidal effect of VMA–13–06 against S. aureus, S. pyogenes, E. coli и K. pneumonia comparable to the comparison drug norfloxacin.